[go: up one dir, main page]

DE69900756D1 - Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung - Google Patents

Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung

Info

Publication number
DE69900756D1
DE69900756D1 DE69900756T DE69900756T DE69900756D1 DE 69900756 D1 DE69900756 D1 DE 69900756D1 DE 69900756 T DE69900756 T DE 69900756T DE 69900756 T DE69900756 T DE 69900756T DE 69900756 D1 DE69900756 D1 DE 69900756D1
Authority
DE
Germany
Prior art keywords
production
cytotoxic effect
medicinal products
hmg proteins
hmg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69900756T
Other languages
English (en)
Other versions
DE69900756T2 (de
Inventor
Alberto Bartorelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SICOR Societa Italiana Corticosteroidi SRL
Original Assignee
ISTITUTO DI RECERCHE GIORGIO S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ISTITUTO DI RECERCHE GIORGIO S filed Critical ISTITUTO DI RECERCHE GIORGIO S
Publication of DE69900756D1 publication Critical patent/DE69900756D1/de
Application granted granted Critical
Publication of DE69900756T2 publication Critical patent/DE69900756T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69900756T 1998-05-19 1999-05-19 Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung Expired - Fee Related DE69900756T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT98MI001094A IT1299583B1 (it) 1998-05-19 1998-05-19 Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
PCT/EP1999/003431 WO1999059609A2 (en) 1998-05-19 1999-05-19 Use of hmg proteins for the preparation of medicaments having cytotoxic activity

Publications (2)

Publication Number Publication Date
DE69900756D1 true DE69900756D1 (de) 2002-02-28
DE69900756T2 DE69900756T2 (de) 2003-03-13

Family

ID=11380053

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69900756T Expired - Fee Related DE69900756T2 (de) 1998-05-19 1999-05-19 Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung

Country Status (10)

Country Link
EP (1) EP1079849B1 (de)
JP (1) JP2002515445A (de)
AT (1) ATE211391T1 (de)
AU (1) AU4363199A (de)
DE (1) DE69900756T2 (de)
DK (1) DK1079849T3 (de)
ES (1) ES2171086T3 (de)
IT (1) IT1299583B1 (de)
PT (1) PT1079849E (de)
WO (1) WO1999059609A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7151082B2 (en) 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
EP1192963A4 (de) * 2000-04-05 2004-08-25 Toray Industries Adsorbentien für proteine der gruppe high mobility protein und säule zum reinigen von körperflüssigkeiten
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
ITMI20011986A1 (it) * 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
WO2003051383A2 (de) * 2001-12-19 2003-06-26 Alcedo Biotech Gmbh Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
GB0226251D0 (en) * 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
EP1668035A2 (de) 2003-09-11 2006-06-14 Critical Therapeutics, Inc. Monoklonale antikörper gegen hmgb1
US8129130B2 (en) 2004-10-22 2012-03-06 The Feinstein Institute For Medical Research High affinity antibodies against HMGB1 and methods of use thereof
CN102731654A (zh) 2004-10-22 2012-10-17 米迪缪尼有限公司 抗hmgb1的高亲和力抗体及其用法
EP1959997A4 (de) 2005-11-28 2009-12-23 Medimmune Llc Antagonisten von hmgb1 und/oder rage und verwendungsverfahren dafür
JP6242050B2 (ja) 2010-01-21 2017-12-06 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 免疫応答を増強するワクチンベクターおよび方法
CN102971008B (zh) 2010-06-09 2015-11-25 阿肯色大学评议会 降低弯曲菌属感染的疫苗和方法
NZ711019A (en) 2013-02-14 2019-07-26 Univ Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
WO2014152508A1 (en) 2013-03-15 2014-09-25 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
JP7467027B2 (ja) 2016-05-03 2024-04-15 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ アーカンソー 免疫刺激性ポリペプチドおよび抗原性ポリペプチドを含む酵母ワクチンベクター並びにそれを使用する方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62166897A (ja) * 1986-01-20 1987-07-23 Toyo Soda Mfg Co Ltd 核内非ヒストン蛋白質に対するモノクロ−ナル抗体
EP0727487A1 (de) * 1995-02-17 1996-08-21 K.U. Leuven Research & Development Multi-Tumor abweichende Wachstumsgene
FR2739292B1 (fr) * 1995-09-28 1997-10-31 Rhone Poulenc Rorer Sa Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations
JP3018313B2 (ja) * 1996-02-23 2000-03-13 雪印乳業株式会社 骨形成促進及び骨吸収防止剤

Also Published As

Publication number Publication date
JP2002515445A (ja) 2002-05-28
PT1079849E (pt) 2002-06-28
EP1079849B1 (de) 2002-01-02
WO1999059609A2 (en) 1999-11-25
ITMI981094A1 (it) 1999-11-19
EP1079849A2 (de) 2001-03-07
AU4363199A (en) 1999-12-06
DE69900756T2 (de) 2003-03-13
ES2171086T3 (es) 2002-08-16
DK1079849T3 (da) 2002-04-22
IT1299583B1 (it) 2000-03-16
WO1999059609A3 (en) 2000-01-27
ATE211391T1 (de) 2002-01-15

Similar Documents

Publication Publication Date Title
DE69900756D1 (de) Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung
DE69713112D1 (de) Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin-analogen
ATE254630T1 (de) Cyclosporine
MX336118B (es) Expresion hibrida y en tandem de proteinas de neisseria.
FI953658A0 (fi) Stabiileja bakterisidisia/läpäisevyyttä parantavia proteiinituotteita ja näitä sisältäviä farmaseuttisia koostumuksia
ATE234867T1 (de) Reaktionsprodukte von hyaluronsäure und natürlichen aminosäuren sowie deren verwendung in kosmetischen und pharmazeutischen zusammensetzungen
DK1109831T3 (da) Cytotoksiske peptider modificeret ved store eller lipofile dele
ATE155486T1 (de) Zyklische peptide und ihre verwendung
DE50004018D1 (de) Verwendung natriuretischer peptide als antibiotisch wirksame substanzen zur behandlung von bakteriellen infektionen
PT848720E (pt) Antagonistas da actividade oncogenica da proteina mdm2 e sua utilizacao no tratamento de cancros
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
DE602004001727D1 (de) Verfahren zur herstellung cyclischer peptide
ATE297750T1 (de) Verwendung von hsp70 protein
ATE364079T1 (de) Peptide mit gdp-austauschfaktorartiger wirkung, dafür kodierende nukleinsäuresequenzen, ihre herstellung und verwendung
HUT58765A (en) Process for producing peptide compounds and pharmaceutical compositions containing them as active components
DE69840024D1 (de) Antimikrobielle Peptide, abstammend von Ubiquicidin
BG103197A (en) Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptiees
ATE86260T1 (de) Peptid-molekuele, wirksam gegen gram-positive keime.
ATE184287T1 (de) Derivate von therapeutisch in der blutgerinnungskaskade wirksamen peptiden, verfahren zur herstellung und sie enthaltende pharmazeutische zubereitungen
DE69812597D1 (de) Peptide zur Inhibition von HPV E7 Proteinen
SE9402332D0 (sv) Igf-1
WO2004013167A3 (en) Purified polypeptides from enterococcus faecalis
WO2004058811A3 (en) Crystal structures of yhhf polypeptides
WO1998051295A1 (fr) Inhibiteur de la protease du vih-1, leur procede de production, et compositions medicinales

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: SICOR SOCIETA ITALIANA CORTICOSTEROIDI S.P.A., MAI

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee